NCT00084656 2022-04-14
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
Bristol-Myers Squibb
Phase 2 Completed
Bristol-Myers Squibb
University of Southern California
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health Clinical Center (CC)